February 23, 2022
Regeneron Pharmaceuticals, Inc. makes the drug Eylea, which is a prescription injection designed to treat wet age-related macular degeneration (wet AMD), an eye disease that can lead to blindness. Eylea is more expensive than the competing drug Avastin, but the complaint for this class action alleges that Regeneron used an illegal scheme involving a purported charity to boost its sales and make it the market leader for wet AMD despite its high prices.
Case Event File: Regeneron “Charity” Boosted Sales of More Expensive Drug ComplaintRelated to: Regeneron “Charity” Boosted Sales of More Expensive Drug Class Action
